# A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin

> **NCT01388335** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 13 (actual)

## Conditions studied

- Solid Tumor
- Lymphoma, Malignant

## Interventions

- **DRUG:** warfarin
- **DRUG:** enzastaurin

## Key facts

- **NCT ID:** NCT01388335
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-10
- **Final completion:** 2012-12
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2020-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01388335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01388335, "A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01388335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*